dp-1

DP-1, a Ganetespib degradation product, represents a fragment derived from SDC-TRAP-0063. Ganetespib itself functions as an inhibitor of heat shock protein 90 (HSP90), exhibiting notable anti-tumor properties.

DP-1 hydrochloride is a degradation product of SDC-TRAP-0063, a fragment of Ganetespib, a heat shock protein 90 (HSP90) inhibitor with antitumor activity.

Flibanserin (Girosa) is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment but has not been linked to instances of clinically apparent acute liver injury.

BW 245C is a selective prostaglandin-like DP receptor (DP1) agonist, a prostaglandin analogue with inhibitory effects on the aggregation response of collagen, which can be used to study diseases such as stroke.

Anisotropine Methylbromide is an anticholinergic agent and has been used for relief of gastrointestinal spasm and for the suppression of gastric acid secretion.

Treprostinil (Orenitram) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

Asapiprant (S-555739) is a potent and selective DP1 receptor antagonist (Ki: 0.44 nM). It exhibited high affinity and selectivity for the DP1 receptor.

Treprostinil diethanolamine (UT-15C) is a potent agonist of EP2, DP1, and IP, with values of 3.6, 4.4, and 32.1 nM for EP2, DP1, and IP, respectively, and 212, 826, 2505, and 4680 nM for EP1, EP4, EP3, and FPKi, respectively. Treprostinil diethanolamine contributes to the upregulation of cAMP, maintaining vascular homeostasis and causing vasodilation in human pulmonary arteries.

Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM).

L 888607 is an effective and selective CRTH2 agonist (Ki: 0.8 nM).

L 888607 Racemate is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1) with Ki values of 132 nM and 17 nM for DP1 and the thromboxane A2 receptor (TP), respectively.

DP-15 acts as a degrader of GSPT1 and BRD4, with DC50 values of 5.25 nM and 0.48 nM, respectively. This compound exhibits antiproliferative activity in AML and NHL cells, showing IC50 values in the nanomolar range, induces G1 phase cell cycle arrest, and triggers apoptosis in MOLM13 cells. Additionally, DP-15 demonstrates anti-leukemic properties in the MOLM-13 xenograft mouse model. [Pink: ligand for target protein JQ-1 carboxylic acid; Black: linker; Blue: ligand for E3 ligaseCereblonThalidomide-5-OH]

THDP-17 is a inhibitor of glutaminase. THDP-17 shows a partial uncompetitive inhibition in vitro.

BDP-13176 is a potent inhibitor of fascin 1(Kd of 90 nM and an IC50 of 240 nM). It has potential as an anti-metastatic agent

Fructo-oligosaccharide DP11/GF10 is a fructooligosaccharide (FOS) with a high degree of polymerization of approximately 11. It consists of multiple fructose units linearly linked via β(2→1) glycosidic bonds, with a glucose residue at the terminal end of the molecule. Fructo-oligosaccharide DP11/GF10 belongs to prebiotic substrates and can be selectively utilized by gut microbiota to modulate the structure and metabolic activity of the intestinal flora.

Fructo-oligosaccharide DP12/GF11 is a fructooligosaccharide (FOS) with a high degree of polymerization of 12. It consists of 11 fructose units linearly linked via β(2→1) glycosidic bonds, with a glucose residue at the terminal end of the molecule. It can be selectively fermented by beneficial gut bacteria, thereby influencing the composition and metabolic function of the intestinal microecology.

Fructo-oligosaccharide DP10/GF9 is a fructan with a degree of polymerisation (DP) of 10, consisting of one D-glucose (Glucose) unit at the non-reducing end and nine fructose (Fructose) units linked by (2→1)-β-glycosidic bonds.

CRTH2-IN-1 is a selective prostaglandin D2 receptor DP2 (CRTH2) antagonist, a Ramatroban analog, with an IC50 of 6 nM in the human DP2 binding assay.

RWJ-445167 is a thrombin and factor Xa dual inhibitor(Ki of 4.0 nM and 230 nM, respectively), with potent antithrombotic activity.

TDP1 Inhibitor-1 is a potent inhibitor of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) with an IC50 of 7 μM.

CX516 (Ampalex), an ampakine and nootropic, acts as an AMPA receptor positive allosteric modulator as a therapy for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).

TDP1 Inhibitor-3 (Compound 4E) is a TDP1 inhibitor with an IC50 value of 0.63 μM.

LMDP10 is an orally active 3-aminoquinazoline derivative that activates the Keap1-Nrf2 pathway. It binds to Keap1, inhibiting the Keap1-Nrf2 interaction and subsequently activating the Nrf2 pathway. This leads to increased levels of Nrf2, SOD, and GSH, while reducing MDA and TNF-α levels. As a result, LMDP10 alleviates neurodegeneration and improves memory in Alzheimer's disease (AD) rat models. LMDP10 is applicable for Alzheimer's disease (AD) research.